{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["96(7)"],"submitter":["Schwake C"],"funding":["Amgen","Roche","AstraZeneca Rare Disease"],"pubmed_abstract":["<h4>Background</h4>Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology. Data on apheresis outcomes in MOGAD attacks remain limited.<h4>Methods</h4>We retrospectively evaluated all apheresis treated attacks occurring in patients with MOGAD between 2008 and 2023 at 18 Neuromyelitis Optica Study Group centres. Treatment response was categorised as complete, partial or no remission. Preattack and follow-up Expanded Disability Status Scale (EDSS) and visual Functional System Scores (FSS) were used to calculate absolute outcomes (ΔEDSS/Δvisual FSS). Predictors of complete remission were analysed using a generalised"],"journal":["Journal of neurology, neurosurgery, and psychiatry"],"pagination":["639-646"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12322437"],"repository":["biostudies-literature"],"pubmed_title":["Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks."],"pmcid":["PMC12322437"],"pubmed_authors":["Neziraj T","Kowarik M","Korsen M","Leypoldt F","Otto C","Graf J","Haarmann A","Mering M","Habedank EM","Frank B","Wandinger KP","Schreiber-Katz O","Stoppe M","Kumpfel T","Wickel J","Bellmann-Strobl J","Giglhuber K","Weber MS","Kaste M","Walter A","Tauber S","Kern K","Sprenger T","Trebst C","Weise J","Geis C","Retzlaff N","Niehaus S","Kern P","Warnke C","Ladopoulos T","Neuhaus O","Pompsch M","Flaskamp M","Hastermann M","Korbel K","Rothammer V","Schwab M","Hoffmann F","Ziemann U","Then Bergh F","Hoffmann O","Wilke C","Kramer M","Duchow A","Liebetrau M","Fischer K","Berthele A","Gingele S","Tumani H","Marziniak M","Siebert N","Rauer S","Melms A","Probstel AK","Buetow F","Hartung HP","Bischof F","Kohler W","Pache F","Maiworm M","Rostasy K","Stephanik H","Albrecht P","Stellmann JP","Klotz L","Schwarz P","Faiss JH","Lee DH","Gutbrod J","Steinbrecher A","Weissert R","Kaulen B","Luessi F","Zipp F","Kowarik MC","Junghans J","Senel M","Ruprecht K","Buttmann M","Schippling S","Korporal-Kuhnke M","Seipelt M","Bayas A","Lindenblatt G","Haußler V","Lauenstein AS","Hummert MW","Sieb JP","Friede T","Niederschweiberer M","Angstwurm K","Ettrich B","Laurent S","Guthke K","Langel S","Husseini L","Godel C","Tunnerhoff J","Ayroza Galvao Ribeiro Gomes AB","Ringelstein M","Schubert C","Paul F","Krumbholz M","Rust R","Tarampanis A","Havla J","Meuth S","Linker R","Sommer C","Behnke S","Kretschmer JR","Pawlitzki M","Kleinschnitz C","Herwerth M","Stefanou A","Bottcher T","Kurka N","Wiendl H","Hellwig K","Herfurth M","Gold R","Ayzenberg I","Jarius S","Bittner S","Pul R","Passoke S","Ruschil C","Mayer C","Metz I","Ruckriem L","Etgen T","Tackenberg B","Gass A","Zettl UK","Neuromyelitis Optica Study Group (NEMOS)","Groppa S","Asseyer S","Wernecke KD","Hemmer B","Yalachkov Y","Aktas O","Kermer P","Schwake C","Kleiter I","Meister S","Winkelmann A","Riedlinger A","Sturner K","Rommer PS","Tkachenko D","Pellkofer H","Zeltner L","Lohmann L","Vardakas I","Walz A","Dawin E","Schindler P","Luedemann P","Suße M","Grothe M","Naumann J","Engels D","Puhlmann HU","Oy UH","Lehrieder D","Spreer A","Wildemann B"],"additional_accession":[]},"is_claimable":false,"name":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.","description":"<h4>Background</h4>Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology. Data on apheresis outcomes in MOGAD attacks remain limited.<h4>Methods</h4>We retrospectively evaluated all apheresis treated attacks occurring in patients with MOGAD between 2008 and 2023 at 18 Neuromyelitis Optica Study Group centres. Treatment response was categorised as complete, partial or no remission. Preattack and follow-up Expanded Disability Status Scale (EDSS) and visual Functional System Scores (FSS) were used to calculate absolute outcomes (ΔEDSS/Δvisual FSS). Predictors of complete remission were analysed using a generalised","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-03-27T17:13:18.18Z","creation":"2025-08-30T03:09:23.45Z"},"accession":"S-EPMC12322437","cross_references":{"pubmed":["39496464"],"doi":["10.1136/jnnp-2024-334863"]}}